Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

Rohmad Yudi Utomo; Satoshi Okada; Akira Sumiyoshi; Ichio Aoki; Hiroyuki Nakamura

doi:10.1039/d2ra00614f

Development of an MRI contrast agent for both detection and inhibition of the amyloid-β fibrillation process

RSC Adv. 2022 Feb 9;12(8):5027-5030. doi: 10.1039/d2ra00614f. eCollection 2022 Feb 3.

Authors

Rohmad Yudi Utomo¹, Satoshi Okada^{1

2

3}, Akira Sumiyoshi⁴, Ichio Aoki⁴, Hiroyuki Nakamura^{1

2}

Affiliations

¹ School of Life Science and Technology, Tokyo Institute of Technology 4259 Nagatsuta, Midori Yokohama Kanagawa 226-8503 Japan.
² Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology 4259 Nagatsuta, Midori Yokohama Kanagawa 226-8503 Japan sokada@res.titech.ac.jp hiro@res.titech.ac.jp.
³ JST, PRESTO 4259 Nagatsuta, Midori Yokohama Kanagawa 226-8503 Japan.
⁴ Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology 4-9-1 Anagawa, Inage Chiba 263-8555 Japan.

Abstract

A curcumin derivative conjugated with Gd-DO3A (Gd-DO3A-Comp.B) was synthesised as an MRI contrast agent for detecting the amyloid-β (Aβ) fibrillation process. Gd-DO3A-Comp.B inhibited Aβ aggregation significantly and detected the fibril growth at 20 μM of Aβ with 10 μM of probe concentration by T ₁-weighted MR imaging.